Cell-free DNA sequencing as a potential screening tool for phase I targeted treatment in refractory/relapse diffuse large B-cell lymphoma

Haematologica. 2022 Aug 1;107(8):1928-1932. doi: 10.3324/haematol.2021.280464.
No abstract available

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Cell-Free Nucleic Acids*
  • Humans
  • Lymphoma, Large B-Cell, Diffuse* / diagnosis
  • Lymphoma, Large B-Cell, Diffuse* / drug therapy
  • Lymphoma, Large B-Cell, Diffuse* / genetics
  • Lymphoma, Non-Hodgkin*
  • Neoplasm Recurrence, Local / pathology
  • Rituximab / therapeutic use
  • Sequence Analysis, DNA

Substances

  • Cell-Free Nucleic Acids
  • Rituximab